Minerva Neurosciences, Inc. KOL Event at New York 2018

New York, November 20, 2018

Please join us for a Minerva Neurosciences KOL Event on 
Tuesday, November 20th, 2018 in New York City

Roluperidone Clinical Update and KOL Insights

KOL Participants: 

Gregory P. Strauss, Ph.D
Assistant Professor,
Director, Clinical Affective Neuroscience Laboratory
Director, Georgia Psychiatric Risk Evaluation Program
Department of Psychology, University of Georgia

David A. Lowe, Ph.D
President and Chief Executive Officer, 
NeuroAssets

For more information or to RSVP, contact Mike Biega at mbiega@troutgroup.com

General Agenda

Agenda & Speakers:

Update on Phase 3 clinical trial with roluperidone
Remy Luthringer, PhD
Executive Chairman & CEO, Minerva Neurosciences, Inc.

Summary of single-dose escalation study with the improved formulation of roluperidone
Jay Saoud, PhD
SVP, Head of Research and Development
Minerva Neurosciences, Inc.

BDNF in CNS diseases: Review of recent BDNF data with roluperidone
David A. Lowe, PhD
Neuro Assets

Trans-diagnostic approach to treating negative symptoms in CNS/psychiatric diseases
Gregory P. Strauss, PhD
Department of Psychology, University of Georgia

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Minerva Neurosciences, Inc. [NERV] US$327 MM MCap
Ph 3 trial w/rolu­peri­done tar­get­ing neg­a­tive symp­toms as­soc w/ schi­zophre­nia; du­al MOA (5-HT2A & Sig­ma2 an­ta­g­on­ist); top-line da­ta 1H19. 3 Ph 2b trials on­go­ing w/ sel­torex­ant, in­clud­ing two in MDD and... [more in­for­ma­tion]